Pfizer Lags Peers Into Monday's Print

PFE gained 1.5% over the past week, trailing the median 2.2% advance across its closest pharmaceutical peers. BMY added 2.9% on the week, NOVN climbed 2.6%, and RPRX led the group with a 4.8% gain. Only PRGO, off 4.0%, and PLRX, also down 4.0%, fared worse. Pfizer closed at $30.03 on Friday, up roughly 7.5% over the past month, continuing the recovery noted in our October 14 note when the stock was trading near $28.37.

Short interest gives little reason for concern either way. At 2.5% of the free float, the bears have a modest footprint and have been retreating: short interest fell around 5% in the month to October 22, with a sharper 4.4% drop in a single session. Borrow availability is effectively unlimited, with no signs of squeeze pressure anywhere in the lending market. The options market is slightly more guarded. The put/call ratio has moved above its 20-day average to 0.84, sitting roughly 1.3 standard deviations above the recent mean, though it remains well below the 52-week high of 0.94. That is caution ahead of a print, not alarm.

The analyst community has continued to drift toward higher price targets without changing ratings. JP Morgan lifted its target to $30, Scotiabank to $33, and HSBC to $30 in the weeks before the print, collectively reversing the wave of cuts seen in July. The consensus stays at hold, with 17 hold ratings against one outperform, but the direction of target revisions has turned constructive. At a P/E of around 10.5x and EV/EBITDA near 9.3x, both multiples have expanded over the past month. The forward earnings trajectory ranks in the 88th percentile year-on-year among peers, a figure that underpins the bull case alongside the company's $60 billion annual sales base and international revenue diversification. Bears continue to focus on gross-to-net adjustments on Vyndaqel and Ibrance, which have the potential to narrow reported revenue regardless of volume trends. Medicaid data from the Centers for Medicare and Medicaid Services adds texture here: units reimbursed through the Medicaid program fell 17% year-on-year in Q1 2026, and Medicaid prescriptions dropped 21% over the same period, though neither dataset has been measured to lead Pfizer's reported financials.

The most striking insider signal came in August, when CEO Albert Bourla bought $1 million worth of stock in an open-market purchase on August 12, a discretionary transaction with no 10b5-1 plan attached. Director Ronald Blaylock matched that commitment almost exactly on August 5, also buying just under $1 million. Net insider buying across the 90-day window reached roughly $2.9 million. The stock is now trading around $30, above the prices at which those purchases were made.

Monday's report will test whether the recovering earnings trajectory is enough to justify the multiple expansion, and whether gross-to-net headwinds on the company's premium drugs are as manageable as the recent wave of target upgrades implies.